



- (51) **International Patent Classification:**
C07K 14/735 (2006.01) *C07K 19/00* (2006.01)
C07K 16/46 (2006.01)
- (21) **International Application Number:**
PCT/US2015/064572
- (22) **International Filing Date:**
8 December 2015 (08.12.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/089,097 8 December 2014 (08.12.2014) US
62/200,557 3 August 2015 (03.08.2015) US
- (71) **Applicant:** 1GLOBE HEALTH INSTITUTE LLC
[US/US]; 333 Providence Highway, Norwood, MA 02062 (US).
- (72) **Inventors:** LI, Chiang, J.; c/o 1Globe Health Institute LLC, 333 Providence Highway, Norwood, MA 02062 (US). UNNIRAMAN, Shyam; c/o 1Globe Health Institute LLC, 333 Providence Highway, Norwood, MA 02062 (US).
- (74) **Agent:** WU, Duan; Milstein Zhang & Wu LLC, 2000 Commonwealth Ave., Ste. 400, Newton, MA 02466 (US).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** SOLUBLE UNIVERSAL ADCC-ENHANCING SYNTHETIC FUSION GENE AND PEPTIDE TECHNOLOGY AND ITS USE THEREOF

Bind antibodies  Engage T cells

CD16
CD32
CD64

Figure 1

(57) **Abstract:** Novel synthetic biology -based ADCC technologies are provided that enhance or enable ADCC responses, for example, through a rationally-designed soluble universal ADCC enhancer protein (SUAEP) where a high-affinity CD3 -binding domain is fused to a high-affinity Fc-binding domain. The SUAEP technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable.